Inhibitory Receptors in Eosinophils of Atopic Subjects | NCT01489293

Studies
Inhibitory Receptors in Eosinophils of Atopic Subjects

NCT01489293

Sponsor

Meir Medical Center

Status

Completed

Last Update Posted

Mar 22, 2018Actual

Enrollment

40Actual

Phase

Not provided

Conditions

Atopy
Atopic Dermatitis
Asthma
Allergic Rhinitis
Food Allergy

Interventions

Not provided

Countries

Israel

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Mar 2018

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

May 1, 2012Actual

Primary Completion Date

Dec 31, 2013Actual

Completion Date

Dec 31, 2013Actual

First Submitted Date

Dec 7, 2011

First Submission Date that Met QC Criteria

Dec 7, 2011

First Posted Date

Dec 9, 2011Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Mar 21, 2018

Last Update Posted Date

Mar 22, 2018Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

Retention

Enrollment

40Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
atopic subjects		Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
non-atopic subjects		Control group without atopic diseases.

Interventions

Not provided

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Expression of surface molecules on eosinophils as assessed by flow cytometry	Blood samples from donors will be stained and evaluated by flow cytomtery	December 2013

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

age 20-60 years
a physician-diagnosed atopic disease

Exclusion Criteria:

atopic disease not active
steroid treatment
active non-atopic inflammatory disease, including infections
pregnancy

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

20 Years

Maximum Age

60 Years

Standard Ages

Adult

Study Population

allergy clinic

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Alon Y Hershko, MD, PhD	Meir Medical Center	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Meir Medical Center. Unit of Allergy and Clinical Immunology		Kfar Saba			Israel

Condition Browse Module

MeSH Terms

ID	Term
D003876	Dermatitis, Atopic
D001249	Asthma
D065631	Rhinitis, Allergic
D005512	Food Hypersensitivity

Ancestor Terms

ID	Term
D012873	Skin Diseases, Genetic
D030342	Genetic Diseases, Inborn
D009358	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
D003872	Dermatitis

Browse Leaves

Not provided

Browse Branches

Not provided